新型降糖药与2型糖尿病患者颈动脉内膜-中层厚度关系
Exploring the Impact of Novel Hypoglycemic Agents on Carotid Intima-Media Thickness in Individuals with Type 2 Diabetes Mellitus
张媚 1刘锐 1赵玉岩2
作者信息
- 1. 吉林大学中日联谊医院特需病房,长春 130000
- 2. 中国医科大学附属第一医院内分泌与代谢病科,沈阳 110000
- 折叠
摘要
2型糖尿病(T2DM)是心血管疾病发生的主要危险因素,可使冠心病和卒中的患病风险增加2倍,老年人中尤为常见.目前对降糖药物研究已经从降低血糖发展为探究独立于降糖作用以外心血管获益阶段.颈动脉内膜-中层厚度(CIMT)是动脉粥样硬化的替代指标,在预测未来心血管事件中具有一定意义.本文综述新型降糖药物对CIMT的影响,揭示CIMT在T2DM临床治疗中的价值.
Abstract
Type 2 diabetes mellitus(T2DM)stands as a significant predisposing factor for cardiovascular diseases,poten-tially doubling the susceptibility to coronary heart disease and stroke,particularly among the elderly population.Current research on hypoglycemic drugs has evolved beyond mere blood glucose reduction to investigating cardiovascular advantages that extend beyond their hypoglycemic effects.Carotid intima-media thickness(CIMT)serves as a surrogate marker for atherosclerosis,carrying considera-ble predictive value for future cardiovascular events.This article critically examines the impact of innovative hypoglycemic drugs on CI-MT,shedding light on the clinical utility of CIMT in the management of T2DM.
关键词
2型糖尿病/新型降糖药物/颈动脉内膜-中层厚度/动脉粥样硬化/心血管疾病Key words
Type 2 diabetes mellitus/Novel hypoglycemic drugs/Carotid intima-media thickness/Atherosclerosis/Cardiovascular disease引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据